Read by QxMD icon Read

diagnosis of prostate cancer

Marc Pretze, Andreas Hien, Matthias Raedle, Ralf Schirrmacher, Carmen Wängler, Björn Wängler
Gold nanoparticles (AuNPs) have widely been used for 70 years in cancer treatment, but only in the last 15 years the focus has been on specific AuNPs with homogeneous size and shape for various areas in science. They constitute a perfect platform for multi-functionalization and therefore enable the enhancement of target affinity. Here we report on the development of tumor specific AuNPs as diagnostic tools intended for the detection of prostate cancer via fluorescence imaging and positron emission tomography (PET)...
March 15, 2018: Bioconjugate Chemistry
Kelly Aubertin, Vincent Quoc Trinh, Michael Jermyn, Paul Baksic, Andrée-Anne Grosset, Joannie Desroches, Karl St-Arnaud, Mirela Birlea, Maria Claudia Vladoiu, Mathieu Latour, Roula Albadine, Fred Saad, Frédéric Leblond, Dominique Trudel
OBJECTIVE: To test if Raman spectroscopy is an appropriate tool for the diagnosis and possibly the grading of prostate cancer. PATIENTS & METHODS: Between 20 and 50 Raman spectra were acquired on 32 fresh and non-processed post-prostatectomy specimens using a macroscopic hand-held Raman spectroscopy probe. Each measured area was characterized and categorized following histopathological criterions like tissue type (extra-prostatic or prostatic), tissue malignancy (benign or malignant), cancer grade (Grade Groups (GG) 1-5), and tissue glandular level...
March 15, 2018: BJU International
Ethan Leng, Benjamin Spilseth, Lin Zhang, Jin Jin, Joseph S Koopmeiners, Gregory J Metzger
PURPOSE: Computer-aided detection/diagnosis (CAD) of prostate cancer (PCa) on multipara-metric MRI (mpMRI) is an active area of research. In the literature, the performance of predictive models trained to detect PCa on mpMRI has typically been reported in terms of voxel-wise mea-sures such as sensitivity and specificity and/or area under the receiver operating curve (AUC).However, it is unclear whether models that score higher by these measures are actually superior.Here, we propose a novel method for lesion identification as well as novel measures that assess the quality of the detected lesions...
March 15, 2018: Medical Physics
Junchao Chen, Clara Oromendia, Joshua A Halpern, Karla V Ballman
PURPOSE: Recent years have brought many changes in the management of localized prostate cancer as national screening guidelines have been updated and diagnostic practice patterns evolved. We sought to better understand how the changing landscape influenced treatment utilization in the United States. METHODS: We used the SEER database in this retrospective analysis of patients with clinically localized prostate cancer between 2004 and 2013. We evaluated utilization of primary treatment modalities over time with descriptive and trend analyses, and examined treatment utilization by cancer risk group and age at diagnosis...
March 14, 2018: Prostate
Hong Truong, Leonard G Gomella, Mathew L Thakur, Edouard J Trabulsi
PURPOSE: Current approaches to prostate cancer screening and diagnosis are plagued with limitations in diagnostic accuracy. There is a compelling need for biomolecular imaging that will not only detect prostate cancer early but also distinguish prostate cancer from benign lesions accurately. In this topic paper, we review evidence that supports further investigation of VPAC1-targeted PET/CT imaging in the primary diagnosis of prostate cancer. METHODS: A non-systematic review of Medline/PubMed was performed...
March 14, 2018: World Journal of Urology
Sunao Shoji, Akio Hashimoto, Tomoya Nakamura, Shinichiro Hiraiwa, Haruhiro Sato, Yoshinobu Sato, Takuma Tajiri, Akira Miyajima
The present study evaluated three-dimensional shear wave elastography (3D SWE) in the detection of clinically significant prostate cancer. Clinically significant prostate cancer was defined by a minimum of one biopsy core with a Gleason score of 3+4 or 6 with a maximum cancer core length >4 mm. Patients with serum prostate-specific antigen levels of 4.0-20.0 ng/ml who were suspected of having prostate cancer from multi-parametric magnetic resonance imaging (mpMRI) were prospectively recruited. The 3D SWE was performed pre-biopsy, after which patients underwent MRI-transrectal ultrasound image-guided targeted biopsies for cancer-suspicious lesions and 12-core systematic biopsies...
April 2018: Biomedical Reports
Jens Sundbøll, Katalin Veres, Erzsébet Horváth-Puhó, Kasper Adelborg, Henrik Toft Sørensen
Background -Venous thromboembolism can be a presenting symptom of cancer, but the association between lower limb arterial thrombosis and cancer is unknown. We therefore examined cancer risk and prognosis of cancer in patients with lower limb arterial thrombosis. Methods -Using nationwide population-based Danish medical registries, we identified all patients diagnosed with first-time lower limb arterial thrombosis (1994-2013) and followed them until the occurrence of any subsequent cancer diagnosis, emigration, death, or 30 November 2013, whichever came first...
March 14, 2018: Circulation
Saira Khan, Veronica Hicks, Danielle Rancilio, Marvin Langston, Katina Richardson, Bettina F Drake
Long-term follow-up care among prostate cancer patients is important as biochemical recurrence can occur many years after diagnosis, with 20%-30% of men experiencing biochemical recurrence within 10 years of treatment. This study examined predictors of follow-up care among 1,158 radical prostatectomy patients, treated at the Washington University in St. Louis, within 6 months, 1 year, and 2 years post surgery. Predictors examined included age at surgery, race (Black vs. White), rural/urban status, education, marital status, and prostate cancer aggressiveness...
March 1, 2018: American Journal of Men's Health
Verena Lieb, Katrin Weigelt, Lena Scheinost, Kersten Fischer, Thomas Greither, Marios Marcou, Gerit Theil, Helmut Klocker, Hans-Juergen Holzhausen, Xin Lai, Julio Vera, Arif B Ekici, Wolfgang Horninger, Paolo Fornara, Bernd Wullich, Helge Taubert, Sven Wach
We studied the association of the serum levels of the microRNA family members miR-320a/-b/-c with clinico-pathological data to assess their applicability as diagnostic biomarker in prostate cancer (PCa) patients. The levels of miR-320a/-b/-c in 3 groups were evaluated by qRT-PCR (145 patients with PCa, 31 patients with benign prostatic hyperplasia (BPH) and 19 healthy controls). The levels of the three family members of miR-320 were directly correlated within each group ( P < 0.001), but they differed significantly among the three groups ( P < 0...
February 13, 2018: Oncotarget
Bjørg Y Aksnessæther, Arne Solberg, Olbjørn H Klepp, Tor Åge Myklebust, Eva Skovlund, Solveig Roth Hoff, Lars J Vatten, Jo-Åsmund Lund
PURPOSE: Prostate cancer (PC) patients who undergo antiandrogen monotherapy are offered prophylactic radiation therapy (PRT) to the breast buds to avoid gynecomastia. The aim of the present study was to evaluate whether the risk of breast cancer (BC) in men with PC as their first cancer diagnosis was influenced by PRT. METHODS AND MATERIALS: From the Norwegian Cancer Registry, we collected data from all patients with PC as their first cancer diagnosis from 1997 to 2014...
February 5, 2018: International Journal of Radiation Oncology, Biology, Physics
Joseph M Unger, Dawn L Hershman, Cathee Till, Catherine M Tangen, William E Barlow, Scott D Ramsey, Phyllis J Goodman, Ian M Thompson
Background: Investigators have used administrative claims to better understand cancer outcomes when a research question cannot feasibly be examined within a study. The Prostate Cancer Prevention Trial (PCPT) showed that seven years of finasteride reduced prostate cancer (PC) risk by 25% in men age 55 years or older. However, it was unclear whether the observed reduction in PC for finasteride participants would be maintained after finasteride discontinuation. Methods: We examined PC diagnoses identified by PCPT study records and Medicare claims (finasteride = 9423, placebo = 9457)...
March 9, 2018: Journal of the National Cancer Institute
Juha Knaapila, Heini Kallio, Antti J Hakanen, Kari Syvänen, Otto Ettala, Esa Kähkönen, Tarja Lamminen, Marjo Seppänen, Ivan Jambor, Antti Rannikko, Jarno Riikonen, Eveliina Munukka, Erkki Eerola, Marianne Gunell, Peter J Boström
OBJECTIVES: To determine, in a prospective, multicenter setting, the prevalence of fluoroquinolone (FQ) resistant and extended spectrum beta lactamase (ESBL) producing E. coli strains in men undergoing transrectal ultrasound guided prostate biopsy (TRUS-Bx) in Finland and to survey the associated risk factors for having the previously mentioned strains. MATERIALS AND METHODS: This is a substudy of the trial investigating the role of magnetic resonance imaging (MRI) in prostate cancer diagnosis (multi-IMPROD, NCT02241122)...
March 13, 2018: BJU International
Karan Lal, Travis J Morrell, Michael Cunningham, Patrick OʼDonnell, Nikki A Levin, Kristine M Cornejo
Cutaneous mixed tumor (chondroid syringoma) is the cutaneous counterpart of pleomorphic adenoma of salivary glands, comprised of both epithelial and mesenchymal components. Malignant transformation is exceptionally rare, with only a few cases reported. We report a case of a malignant cutaneous mixed tumor in an 86-year-old white man who presented with a pink indurated plaque on his left scapula. He had a history of nonmelanoma skin cancers, a stage IB malignant melanoma of a lower extremity and Gleason 4 + 3 prostate cancer treated with brachytherapy, external beam irradiation, and bicalutamide...
March 6, 2018: American Journal of Dermatopathology
Susanne Blödt, Maleen Kaiser, Yvonne Adam, Sandra Adami, Martin Schultze, Jacqueline Müller-Nordhorn, Christine Holmberg
OBJECTIVE: To analyse the role and meaning of health information in individuals' experiences with either breast, colorectal or prostate cancer in order to better understand unmet information needs of people with a cancer diagnosis. DESIGN: This is a secondary analysis of data from a qualitative interview study including narrative interviews and maximum variation sampling. A thematic analysis was conducted, followed by an in-depth analysis based on the principles of grounded theory...
March 12, 2018: BMJ Open
Mariela Varsavsky, Manuel Romero Muñoz, Verónica Ávila Rubio, Antonio Becerra, Antonia García Martín, Guillermo Martínez Díaz-Guerra, Pedro Rozas Moreno, Esteban Jódar Gimeno, Manuel Muñoz Torres
OBJECTIVE: To provide practical recommendations to assess and treat osteoporosis in males. PARTICIPANTS: Members of the Bone Metabolism Working Group of the Spanish Society of Endocrinology. METHODS: Recommendations were formulated using the GRADE system (Grading of Recommendations, Assessment, Development, and Evaluation) to describe both the strength of recommendations and the quality of evidence. A systematic search was made in Medline (PubMed) using the following associated terms: «osteoporosis», «men», «fractures», «bone mineral density», «treatment», «hypogonadism», and «prostate cancer»...
March 9, 2018: Endocrinología, Diabetes y Nutrición
Sangeeta Taneja, Amarnath Jena, Rajesh Taneja, Aru Singh, Aashim Ahuja
OBJECTIVE: The purpose of this study is to assess whether temporal changes in68 Ga-prostate-specific membrane antigen (PSMA)-HBED-CC uptake and multiparametric MRI parameters derived using PET/MRI can aid in characterization of benign and malignant prostate lesions. MATERIALS AND METHODS: Thirty-five men with 29 malignant and six benign prostate lesions undergoing complete clinical workup including histologic analysis were enrolled for this retrospective study. All had undergone simultaneous whole-body68 Ga-PSMAHBED-CC PET/MRI...
March 12, 2018: AJR. American Journal of Roentgenology
Sara Bravaccini, Maurizio Puccetti, Martine Bocchini, Sara Ravaioli, Monica Celli, Emanuela Scarpi, Ugo De Giorgi, Maria Maddalena Tumedei, Giandomenico Raulli, Loredana Cardinale, Giovanni Paganelli
Prostate cancer (PCa) patients are risk-stratified on the basis of clinical stage and PSA level at diagnosis and the Gleason Score (GS) in prostate biopsy. However, these parameters are not completely accurate in discriminating between high- and low-risk disease, creating a need for a reliable marker to determine aggressiveness. Prostate-specific membrane antigen (PSMA) appears to fulfill this need. We analyzed 79 prostate biopsies and 28 prostatectomies to assess whether PSMA expression detected by immunohistochemistry is related to GS...
March 9, 2018: Scientific Reports
Visalini Nair-Shalliker, Albert Bang, Marianne Weber, David E Goldsbury, Michael Caruana, Jon Emery, Emily Banks, Karen Canfell, Dianne L O'Connell, David P Smith
Australia has one of the highest incidence rates of prostate cancer (PC) worldwide, due in part to widespread prostate specific antigen (PSA) testing. We aimed to identify factors associated with PSA testing in Australian men without a diagnosis of prostate cancer or prior prostate disease. Participants were men joining the 45 and Up Study in 2006-2009, aged ≥45 years at recruitment. Self-completed questionnaires were linked to cancer registrations, hospitalisations, health services data and deaths. Men with a history of PC, radical prostatectomy or a "monitoring" PSA test for prostate disease were excluded...
March 9, 2018: Scientific Reports
Haidy E Zidan, Rehab S Abdul-Maksoud, Walid S H Elsayed, Esam A M Desoky
Prostate cancer (PCa) is considered the most common malignancy in men. The aim of this study is to assess the role of serum miR-15a and miR-16-1 expression in PCa development, diagnosis and prognosis aiming to find a specific noninvasive biomarker. This study comprised 70 patients with PCa, 70 patients complaining of benign prostatic hyperplasia (BPH), 30 patients with chronic prostatitis and 70 controls. Circulating miR-15a and miR-16-1 expression was detected by real-time polymerase chain reaction. Prostate specific antigen levels were measured by enzyme-linked immunosorbent assay...
March 9, 2018: IUBMB Life
Adriana C Vidal, Lauren E Howard, Amanda de Hoedt, Christopher J Kane, Martha K Terris, William J Aronson, Matthew R Cooperberg, Christopher L Amling, Stephen J Freedland
OBJECTIVE: At the population level, obesity is associated with prostate cancer (PC) mortality; however, some studies found higher body mass index (BMI) is associated with better long-term PC outcomes among men with metastatic castration-resistant PC (mCRPC). PATIENTS AND METHODS: We tested whether obesity was associated with progression to metastasis, PC-specific mortality (PCSM), and all-cause mortality (ACM) among 1192 non-metastatic CRPC patients from the SEARCH Database...
March 9, 2018: BJU International
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"